Ipamorelin + CJC-1295 Stack: Research Guide

The Ipamorelin + CJC-1295 stack pairs a selective GH-releasing peptide (Ipamorelin) with a GHRH analog (CJC-1295) that hit different receptors in the growth hormone axis, producing a cleaner, more pulsatile GH release than either compound does alone. Of all the growth hormone peptides sold for research, this combination is the single most cited stack in 2026.

How Each Peptide Works

Ipamorelin is a selective GHRP (growth hormone releasing peptide). It binds the ghrelin receptor and triggers a sharp pulse of growth hormone, without significantly raising cortisol or prolactin (a key advantage over older GHRPs like GHRP-6 and GHRP-2).(1)

CJC-1295 is a GHRH analog (growth hormone releasing hormone). It increases the *amplitude* of natural GH pulses by mimicking the hypothalamic signal. Two versions exist:

• •CJC-1295 no-DAC (also called Mod GRF 1-29): short half-life, ~30 minutes, mirrors natural GH pulsatility
• •CJC-1295 DAC: half-life of ~6-8 days, drives a continuous GH "bleed", shown in healthy-adult trials to produce prolonged GH and IGF-1 elevation(2)

For most research protocols studying physiological GH patterns, no-DAC is preferred because it preserves the natural pulse architecture.

Why Stack Them?

GHRPs and GHRHs work through synergistic pathways. Combining them produces a GH release that is several times larger than either alone. The stack mimics how the body naturally co-releases ghrelin and GHRH signals.

Published research on GHRP/GHRH co-administration has generally used ipamorelin alongside CJC-1295 (no-DAC) in a roughly 1:1 mass ratio, reflecting the two peptides' complementary receptor targets rather than an additive combination of two independent effects.

What the Research Shows

Studies on GHRP/GHRH co-administration have documented:

• •5 to 10x larger GH peaks vs. either peptide alone
• •Increased IGF-1 levels with sustained protocols
• •Improved sleep quality metrics (deep sleep stages linked to nighttime GH pulses)
• •Enhanced recovery markers in athletic research populations

For a deeper look at the cellular pathways, see our companion article on growth hormone peptides explained.

Reported Adverse Effects in the Literature

Compared to older GH-axis compounds, research populations studied with this combination generally tolerated it well, though published data report some adverse effects:

• •Water retention, most commonly in early-phase administration
• •Paresthesia (tingling or numbness in extremities), described as mild and carpal-tunnel-like
• •Increased appetite, consistent with ghrelin receptor activation
• •Injection-site reactions, transient, in animal and in-vitro administration studies

Storage & Reconstitution

Both peptides ship as lyophilized powder. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days. See our peptide storage guide for the complete protocol.

Buying Ipamorelin and CJC-1295 in the USA

When sourcing this stack, verify:

• •HPLC purity ≥99% with batch-specific COA
• •Mass spectrometry confirmation of sequence
• •Clear DAC vs. no-DAC labeling on CJC-1295
• •Lyophilized vials, not pre-mixed
• •Cold-chain dispatch from a US warehouse

Browse our research-grade Ipamorelin and CJC-1295 with full COAs available on request, or use the dosing calculator to plan your protocol.

Frequently Asked Questions

Is Ipamorelin stronger than CJC-1295?

They work differently. Ipamorelin triggers a sharp GH pulse via the ghrelin receptor, while CJC-1295 amplifies the body's existing GH pulses via the GHRH receptor. Stacking them is more effective than either alone.

Should I use CJC-1295 with or without DAC?

For research protocols modeling physiological GH release, no-DAC is preferred because it preserves natural pulsatility. DAC is studied more in sustained-release research models.

What does the literature say about long-term administration?

Continuous administration is associated with receptor downregulation in the literature, which is why published research designs generally study intermittent rather than continuous administration schedules. This article does not provide an administration protocol; consult the primary literature and institutional research protocols directly.

What purity should I look for?

99% or higher HPLC-verified, with mass spec confirmation on the batch COA.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822.
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683.

*Disclaimer: All products referenced are intended strictly for in-vitro laboratory research and are not approved by the FDA for human consumption or therapeutic use.*